Statement on news that NICE does not intend to approve omalizumab (Xolair) for use in children aged 6-11

‘The Scottish Medicines Consortium (SMC) has already approved this life-changing drug for use in children aged 6-11 in Scotland, so yet again, patients could be faced with a treatment postcode lottery depending on where they live in the UK.

‘Every child deserves the best possible start in life, yet those with conditions like severe asthma are held back by crippling daily symptoms, endless trips to hospital and huge amounts of time off school, which severely hinders their life chances and ability to form relationships.

‘Xolair could provide a lifeline for some of these children, giving them an opportunity to experience a normal childhood and take part in activities that have been difficult or even impossible, like playing sports with their friends or managing a full night’s sleep without suffering an asthma attack.

‘We therefore urge NICE to re-consider this decision as a matter of priority.’

Healthcanal Staff
About Healthcanal Staff

HealthCanal Editorial team is a team of high standard writers, who qualified the strict entrance test of Health Canal. The team involves in both topic researching and writting, which are under supervision and controlled by medical doctors of medical team.